#lenvatinib
LightNews LightNews
biologist077.bsky.social
FDA approved Belzutifan + Lenvatinib for advanced kidney cancer after immunotherapy. In a trial (747 pts), it extended time before cancer worsened to 14.6 vs 10.6 months. What does an extra 4 months of stable disease truly mean for these patients?
FDA Approves Belzutifan in Combination with Lenvatinib for Advanced Kidney Cancer Post-Immunotherapy
The U.S. Food and Drug Administration (FDA) has approved a new combination treatment consisting of belzutifan (Welireg) and lenvatinib (Lenvima) for adults battling advanced renal cell carcinoma, a ty
www.fda.gov
September 25, 2026 at 8:02 AM
mskcancercenter.bsky.social
The FDA has approved the drug belzutifan in combination with lenvatinib for patients with a type of #kidneycancer called clear cell renal cell carcinoma (ccRCC).

The approval was based on a clinical trial led by Dr. Robert Motzer, a genitourinary medical oncologist at MSK. https://bit.ly/4hiaiJO
September 30, 2026 at 6:12 PM
shakiramrfr.bsky.social
Lenvatinib Mesilate Capsules Market Analysis & Forecast 2035 | WiseGuyReports www.wiseguyreports.com/reports/lenv...
www.wiseguyreports.com
September 29, 2026 at 8:20 AM
robbrierley.bsky.social
New research - TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

www.thelancet.com/journals/lan...

@thelancet.bsky.social #MedSky #OncSky #LiverSky
January 9, 2025 at 8:09 AM
onclive.bsky.social
Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC @ascocancer.bsky.social #GU25

www.onclive.com/view/lenvati...
Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC
Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.
www.onclive.com
February 15, 2025 at 7:08 PM
yukselurun.bsky.social
CLEAR study biomarker analysis: Lenvatinib + Pembrolizumab improved ORR/PFS vs. sunitinib in aRCC, consistent across PD-L1, 🧬gene expression, mutations, subtypes. @drchoueiri.bsky.social @oncoalert.bsky.social @kidney-cancer.bsky.social
December 14, 2024 at 12:55 PM
medical-research.bsky.social
🚨 New hope for liver cancer patients! 🧪 The LEAP-012 trial shows that adding lenvatinib + pembrolizumab to TACE significantly extends progression-free survival in intermediate-stage hepatocellular carcinoma HCC.

📚💙 #LiverCancer #MedicalBreakthrough #medschool #medsky #medical #research #cancer
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
TACE plus lenvatinib plus pembrolizumab showed significant, clinically meaningful improvement in progression-free survival in patients with unresectable, non-metastatic hepatocellular carcinoma compared with TACE plus placebo. The numerical improvement in overall survival is encouraging, but longer follow-up is necessary.
www.thelancet.com
January 11, 2025 at 2:50 AM
labwaggoner.bsky.social
In HCC patients treated with anti-PD-1 and lenvatinib, a circulating effector memory CD8+ T cell population is critical for treatment efficacy
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/... preview by @meganburgerphd.bsky.social
@cp-cancercell.bsky.social
January 30, 2025 at 10:11 PM
cancerletter.com
FDA approves belzutifan in combination with lenvatinib for advanced RCC with a clear cell component
https://cancerletter.com/drugs-and-targets/20260925_10b/
FDA approves belzutifan in combination with lenvatinib for advanced RCC with a clear cell component - The Cancer Letter
FDA has approved belzutifan (Welireg) in combination with lenvatinib (Lenvima) for adults with advanced renal cell carci
cancerletter.com
September 27, 2026 at 6:00 PM
cressidaseymour88.bsky.social
FDA approved belzutifan plus lenvatinib for certain patients with advanced renal cell carcinoma after prior PD-1/PD-L1 therapy. It adds another option to the increasingly complex sequence of immunotherapy and targeted treatment
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology.
www.fda.gov
September 27, 2026 at 3:22 PM
onclive.bsky.social
Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC @winshipatemory.bsky.social @ascocancer.bsky.social #GU25 #kcsm #oncology
www.onclive.com/view/periope...
Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC
Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.
www.onclive.com
February 15, 2025 at 7:29 PM
pomonaka.bsky.social
Got my scan results just now - no evidence of residual disease! (And nothing new either!) Next is to find out how long I have to stay on this damned lenvatinib. So, back with NED, but now I know it’s a fickle relationship & won’t last. But I will enjoy it while it does!
January 18, 2025 at 1:39 AM
sadlersnaps.bsky.social
Some news for us in the #kidneycancer landscape. #Cansky

us.eisai.com/press-releas...
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) | Eisai US
RAHWAY, N.J., and NUTLEY, N.J., Sept. 25, 2026 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the U.S. Food and Drug Administration (FDA) has appr...
us.eisai.com
September 25, 2026 at 11:32 PM
acochran12733.bsky.social
New in #JCO First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial #openaccess #gynonc #oncsky ascopubs.org/doi/10.1200/...
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial | Journal of Clinical Oncology
PURPOSELenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent end...
ascopubs.org
November 27, 2024 at 4:21 PM
oncodaily.bsky.social
LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LEVIATHAN #Lenvatinib #Sorafenib #HepatocellularCarcinoma #HCC
LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma - OncoDaily
Lenvatinib shows superior survival over sorafenib as second-line therapy after A+B in HCC, per multinational real-world LEVIATHAN study.
oncodaily.com
September 27, 2025 at 2:17 PM
leannewoods.bsky.social
My husband was diagnosed with metastatic renal cell carcinoma in June and started ipil/nivo but had a severe reaction and was moved onto lenvatinib & Pembrolizumab in September, his blood work has improved, weight stabilised & CT scan at Xmas showed the primary tumour shrinking.
January 13, 2025 at 7:34 AM
abhishekgarglab.bsky.social
#TUG1 targeting enhances #anticancer #immunity thereby facilitating #lenvatinib efficacy in #hepatocellular #carcinoma

#Genes & #Immunity @springernature.com
www.nature.com/articles/s41...
TUG1 targeting enhances anticancer immunity thereby facilitating lenvatinib efficacy in hepatocellular carcinoma - Genes & Immunity
Genes & Immunity - TUG1 targeting enhances anticancer immunity thereby facilitating lenvatinib efficacy in hepatocellular carcinoma
www.nature.com
September 19, 2025 at 1:03 PM
natcancer.nature.com
Article now published @NatureCancer !

'Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial'

✒️By Ye Li, Peng Wang and colleagues

🔗 www.nature.com/articles/s43...
Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial - Nature Cancer
Wang and colleagues report the clinical results and immunological correlates of a phase 2 clinical trial of cryoablation plus lenvatinib and sintilimab in persons with advanced or metastatic intrahepa...
www.nature.com
November 19, 2025 at 11:45 AM
mskdeptofmed.bsky.social
At @ascocancer.bsky.social #GU26, Robert Motzer presented phase 3 trial results that showed belzutifan + lenvatinib achieved superior PFS & ORR compared with cabozantinib in people with advanced #kidneycancer who progressed after immunotherapy. @mskcancercenter.bsky.social

🔗 https://bit.ly/4r4AYPD
February 28, 2026 at 5:25 PM
realbiomassspec.bsky.social
Sensitive quantification of free lenvatinib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and the clinical significance of measuring free lenvatinib concentration #CCA www.sciencedirect.com/science/arti...
Sensitive quantification of free lenvatinib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and the clinical significance of measuring free lenvatinib concentrat...
Lenvatinib, an oral molecular target drug used for the treatment of hepatocellular carcinoma (HCC), has a high protein binding rate, resulting in high…
www.sciencedirect.com
February 11, 2025 at 10:45 AM
oncodaily.bsky.social
Five articles suggested by Yüksel Ürün
@yukselurun.bsky.social

oncodaily.com/science/yuks...

#AnkaraUniversity #BRCA #Cancer #FightAgainstCancer #Lenvatinib #mCRPC #mpMRI #OncoDaily #Oncology #Pembrolizumab #ProstateCancer #UrothelialCarcinoma
Five articles suggested by Yüksel Ürün - OncoDaily
Five articles suggested by Yüksel Ürün / Ankara University School of Medicine, BRCA, cancer, Charlie A. Hamm, CLEAR, Elizabeth J.Schafer, fight against
oncodaily.com
December 15, 2024 at 4:56 PM
pomonaka.bsky.social
Of course, my semi-functional port (flushable but no blood return) worked perfectly at the fluoro check. 🤷 But that means it can be used tomorrow for my VIP (Very Important PET) tomorrow which will determine if the brachy/pembro/lenvatinib worked. Cue scanxiety in 3, 2, 1…
January 15, 2025 at 6:11 PM
natrevclinonc.nature.com
Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC
Nature Reviews Clinical Oncology, Published online: 27 August 2026; doi:10.1038/s41571-026-01200-8Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC
dlvr.it
August 27, 2026 at 8:07 AM
mskdeptofmed.bsky.social
#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib plus pembrolizumab in advanced #endometrialcancer. @mskcancercenter.bsky.social

➡️ bit.ly/3JncnWA
October 21, 2025 at 3:28 PM
tommytang.bsky.social
Circulating T cells fuel anti-PD-1 and lenvatinib efficacy www.cell.com/cancer-cell...
February 19, 2025 at 2:45 PM